Selective loss of dopaminergic neurons in the substantia nigra of Pitx3-deficient aphakia mice

Molecular Brain Research

Volumn 114, Issue 2, 2003, Pages 123-131

  Hwang, Dong Youn ^a   Ardayfio, Paul ^a   Kang, Un Jung ^b   Semina, Elena V ^c   Kim, Kwang Soo ^a,d  

^a MCLEAN HOSPITAL   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

^c MEDICAL COLLEGE OF WISCONSIN   (United States)

^d MRC 215 ^*  (United States)

Author keywords

A10 neurons; A9 neurons; ak Mice; DA neuron development; Dopamine; Parkinson's disease; Pitx3; Substantia nigra pas compacta; Ventral tegmental area

Indexed keywords

DOPAMINE; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR PITX3; UNCLASSIFIED DRUG;

ANIMAL TISSUE; APHAKIA; ARTICLE; CELL LOSS; CONTROLLED STUDY; CORPUS STRIATUM; DEVELOPMENTAL STAGE; DISEASE SEVERITY; DOPAMINE BRAIN LEVEL; DOPAMINERGIC NERVE CELL; MOUSE; NERVE CELL DEGENERATION; NERVE CELL DIFFERENTIATION; NERVE PROJECTION; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; NUCLEOTIDE SEQUENCE; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SUBSTANTIA NIGRA;

EID: 0037786542     PISSN: 0169328X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-328X(03)00162-1     Document Type: Article

References (31)

1. Bernheimer H., Birkmayer W., Hornykiewicz O., Jellinger K., Seitelberger F. Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. J. Neurol. Sci. 20:1973;415-455.
2. Bjorklund A., Lindvall O. Cell replacement therapies for central nervous system disorders. Nat. Neurosci. 3:2000;537-544.
3. Castillo S.O., Baffi J.S., Palkovits M., Goldstein D.S., Kopin I.J., Witta J., Magnuson M.A., Nikodem V.M. Dopamine biosynthesis is selectively abolished in substantia nigra/ventral tegmental area but not in hypothalamic neurons in mice with targeted disruption of the Nurr1 gene. Mol. Cell. Neurosci. 11:1998;36-46.
4. Chang J.W., Wachtel S.R., Young D., Kang U.J. Biochemical and anatomical characterization of forepaw adjusting steps in rat models of Parkinson's disease: studies on medial forebrain bundle and striatal lesions. Neuroscience. 88:1999;617-628.
5. Chung S., Sonntag K.C., Andersson T., Bjorklund L.M., Park J.J., Kim D.W., Kang U.J., Isacson O., Kim K.S. Genetic engineering of mouse embryonic stem cells by Nurr1 enhances differentiation and maturation into dopaminergic neurons. Eur. J. Neurosci. 16:2002;1829-1838.
6. Crawley J.N., Paylor R. A proposed test battery and constellations of specific behavioral paradigms to investigate the behavioral phenotypes of transgenic and knockout mice. Horm. Behav. 31:1997;197-211.
7. Dawson T.M., Dawson V.L. Neuroprotective and neurorestorative strategies for Parkinson's disease. Nat. Neurosci. 5:(Suppl.):2002;1058-1061.
8. Goridis C., Rohrer H. Specification of catecholaminergic and serotonergic neurons. Nat. Rev. Neurosci. 3:2002;531-541.
9. Hwang D.Y., Carlezon W.A. Jr., Isacson O., Kim K.S. A high-efficiency synthetic promoter that drives transgene expression selectively in noradrenergic neurons. Hum. Gene. Ther. 12:2001;1731-1740.
10. Hynes M., Rosenthal A. Specification of dopaminergic and serotonergic neurons in the vertebrate CNS. Curr. Opin. Neurobiol. 9:1999;26-36.
11. Kim J.H., Auerbach J.M., Rodriguez-Gomez J.A., Velasco I., Gavin D., Lumelsky N., Lee S.H., Nguyen J., Sanchez-Pernaute R., Bankiewicz K., McKay R. Dopamine neurons derived from embryonic stem cells function in an animal model of Parkinson's disease. Nature. 418:2002;50-56.
12. Koob G.F. Drugs of abuse: anatomy, pharmacology and function of reward pathways. Trends Pharmacol. Sci. 13:1992;177-184.
13. Kordower J.H., Emborg M.E., Bloch J., Ma S.Y., Chu Y., Leventhal L., McBride J., Chen E.Y., Palfi S., Roitberg B.Z., Brown W.D., Holden J.E., Pyzalski R., Taylor M.D., Carvey P., Ling Z., Trono D., Hantraye P., Deglon N., Aebischer P. Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease. Science. 290:2000;767-773.
14. Le W., Conneely O.M., Zou L., He Y., Saucedo-Cardenas O., Jankovic J., Mosier D.R., Appel S.H. Selective agenesis of mesencephalic dopaminergic neurons in Nurr1-deficient mice. Exp. Neurol. 159:1999;451-458.
15. Lim K.C., Lakshmanan G., Crawford S.E., Gu Y., Grosveld F., Engel J.D. Gata3 loss leads to embryonic lethality due to noradrenaline deficiency of the sympathetic nervous system. Nat. Genet. 25:2000;209-212.
16. Rieger D.K., Reichenberger E., McLean W., Sidow A., Olsen B.R. A double-deletion mutation in the Pitx3 gene causes arrested lens development in aphakia mice. Genomics. 72:2001;61-72.
17. Saucedo-Cardenas O., Quintana-Hau J.D., Le W.D., Smidt M.P., Cox J.J., De Mayo F., Burbach J.P., Conneely O.M. Nurr1 is essential for the induction of the dopaminergic phenotype and the survival of ventral mesencephalic late dopaminergic precursor neurons. Proc. Natl. Acad. Sci. USA. 95:1998;4013-4018.
18. Seeman P., Guan H.C., Van Tol H.H. Dopamine D4 receptors elevated in schizophrenia. Nature. 365:1993;441-445.
19. Semina E.V., Ferrell R.E., Mintz-Hittner H.A., Bitoun P., Alward W.L., Reiter R.S., Funkhauser C., Daack-Hirsch S., Murray J.C. A novel homeobox gene PITX3 is mutated in families with autosomal-dominant cataracts and ASMD. Nat. Genet. 19:1998;167-170.
20. Semina E.V., Murray J.C., Reiter R., Hrstka R.F., Graw J. Deletion in the promoter region and altered expression of Pitx3 homeobox gene in aphakia mice. Hum. Mol. Genet. 9:2000;1575-1585.
21. Semina E.V., Reiter R.S., Murray J.C. Isolation of a new homeobox gene belonging to the Pitx/Rieg family: expression during lens development and mapping to the aphakia region on mouse chromosome 19. Hum. Mol. Genet. 6:1997;2109-2116.
22. Smidt M.P., Asbreuk C.H., Cox J.J., Chen H., Johnson R.L., Burbach J.P. A second independent pathway for development of mesencephalic dopaminergic neurons requires Lmx1b. Nat. Neurosci. 3:2000;337-341.
23. Smidt M.P., van Schaick H.S., Lanctot C., Tremblay J.J., Cox J.J., van der Kleij A.A., Wolterink G., Drouin J., Burbach J.P. A homeodomain gene Ptx3 has highly restricted brain expression in mesencephalic dopaminergic neurons. Proc. Natl. Acad. Sci. USA. 94:1997;13305-13310.
24. van Domburg P.H., ten Donkelaar H.J. The human substantia nigra and ventral tegmental area. A neuroanatomical study with notes on aging and aging diseases. Adv. Anat. Embryol. Cell Biol. 121:1991;1-132.
25. Varnum D.S., Stevens L.C. Aphakia, a new mutation in the mouse. J. Hered. 59:1968;147-150.
26. Vila M., Wu D.C., Przedborski S. Engineered modeling and the secrets of Parkinson's disease. Trends Neurosci. 24:2001;S49-55.
27. Ye W., Shimamura K., Rubenstein J.L., Hynes M.A., Rosenthal A. FGF and Shh signals control dopaminergic and serotonergic cell fate in the anterior neural plate. Cell. 93:1998;755-766.
28. Zetterstrom R.H., Solomin L., Jansson L., Hoffer B.J., Olson L., Perlmann T. Dopamine neuron agenesis in Nurr1-deficient mice. Science. 276:1997;248-250.
29. Zhou Q.Y., Palmiter R.D. Dopamine-deficient mice are severely hypoactive, adipsic, and aphagic. Cell. 83:1995;1197-1209.
30. Wachtel S.R., Bencsics C., Kang U.J. Role of aromatic L-amino acid decarboxylase for dopamine replacement by genetically modified fibroblasts in a rat model of Parkinson's disease. J. Neurochem. 69:1997;2055-2063.
31. M.M. Bradford, A rapid and sensitive method for the quantification of microgram quantities of protein utilizing the principle of protein-dye binding, Anal. Biochem. (1976) 248-254.